Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity
Authors:
- 1 May 2005
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (9) , 3514-3522
Abstract
Purpose: Circulating endothelial cells (CEC) comprise at least two distinct populations: bone marrow–derived circulating endothelial progenitors (CEP) and mature CECs derived from existing vasculature. We hypothesized that antiangiogenic agents may have differential effects on CEPs and mature CECs and that these changes may serve as a marker of biological activity. Experimental Design: The effect of angiogenesis inhibitors on CECs was evaluated by flow cytometry after vascular endothelial growth factor (VEGF)–induced mobilization and in mice bearing Lewis lung carcinoma (LLC). Tumor angiogenesis was evaluated in parallel by immunohistochemistry. Results: In nontumor-bearing mice, VEGF administration increased both mature CECs and CEPs. This increase was inhibited by the VEGF receptor 2 inhibitor ZD6474 as well as the VEGF inhibitor–soluble Flt-1. ZD6474 had no significant effect on CECs in the absence of exogenous VEGF stimulation. In contrast, LLC-bearing mice had an increase in mature CECs but not CEPs after 3 days of treatment with ZD6474. The increase in mature CECs was dose-dependent, accompanied by a decrease in tumor microvessel density, and preceded reduction in tumor volume. Treatment of LLC-bearing mice with the vascular targeting agent ZD6126 also increased mature CECs. Conclusions: VEGF inhibitors can have differential effects on mature CECs and CEPs, and agents inhibiting tumor angiogenesis may cause a concomitant increase in mature CECs. This increase occurs in tumor-bearing but not in nontumor-bearing mice, suggesting that tumor endothelium is a potential source of mature CECs. Therefore, assessing both mature CECs and CEPs may provide insights into the mechanism of antiangiogenic agents and serve as an early surrogate marker of biological activity.Keywords
This publication has 39 references indexed in Scilit:
- Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord bloodBlood, 2004
- Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue SarcomasClinical Cancer Research, 2004
- Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane GhostsThe American Journal of Pathology, 2004
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Hematopoietic stem cells and endothelial cell precursors express Tie-2, CD31 and CD45Blood Cells, Molecules, and Diseases, 2004
- Genetic loci that control vascular endothelial growth factor‐induced angiogenesisThe FASEB Journal, 2003
- Vascular Endothelial Growth Factor Receptor-2 Induces Survival of Hematopoietic Progenitor CellsJournal of Biological Chemistry, 2003
- Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-rasGenes & Development, 2001
- Origins of circulating endothelial cells and endothelial outgrowth from bloodJournal of Clinical Investigation, 2000
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971